Guo S - Search Results

1

A pilot study of short-term high-pressure support ventilation in persistent sudden-onset rapid breathing.

Duan J, Tang X, Huang S, Jia J, Guo S. Duan J, et al. Among authors: guo s. Anaesth Intensive Care. 2012 Nov;40(6):971-9. doi: 10.1177/0310057X1204000608. Anaesth Intensive Care. 2012. PMID: 23194206

2

Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.

Geng D, Guo Q, Huang S, Zhang H, Guo S, Li X. Geng D, et al. Among authors: guo q, guo s. Clin Transl Oncol. 2022 Feb;24(2):379-387. doi: 10.1007/s12094-021-02701-x. Epub 2021 Aug 28. Clin Transl Oncol. 2022. PMID: 34453698

3

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.

Yan N, Huang S, Li L, Guo Q, Geng D, Zhang H, Guo S, Li X. Yan N, et al. Among authors: guo q, guo s. Front Pharmacol. 2022 Sep 9;13:898623. doi: 10.3389/fphar.2022.898623. eCollection 2022. Front Pharmacol. 2022. PMID: 36160430 Free PMC article.

4

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience.

Yan N, Guo S, Huang S, Zhang H, Li X. Yan N, et al. Among authors: guo s. Front Oncol. 2024 Feb 22;14:1331128. doi: 10.3389/fonc.2024.1331128. eCollection 2024. Front Oncol. 2024. PMID: 38454923 Free PMC article.

5

Case report: The effect of second-line vebreltinib treatment on a patient with advanced NSCLC harboring the MET exon 14 skipping mutation after tepotinib treatment.

Huang S, Li L, Yan N, Zhang H, Guo Q, Guo S, Geng D, Liu X, Li X. Huang S, et al. Among authors: guo q, guo s. Front Oncol. 2024 Apr 19;14:1331387. doi: 10.3389/fonc.2024.1331387. eCollection 2024. Front Oncol. 2024. PMID: 38706592 Free PMC article.

6

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience.

Yan N, Guo S, Huang S, Zhang H, Li X. Yan N, et al. Among authors: guo s. Front Oncol. 2024 Jun 3;14:1412472. doi: 10.3389/fonc.2024.1412472. eCollection 2024. Front Oncol. 2024. PMID: 38887239 Free PMC article.

7

Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: A single‑institution experience.

Yan N, Guo S, Zhang Z, Shen S, Li X. Yan N, et al. Among authors: guo s. Oncol Lett. 2024 Jan 31;27(3):135. doi: 10.3892/ol.2024.14268. eCollection 2024 Mar. Oncol Lett. 2024. PMID: 38357477 Free PMC article.

8

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report.

Yan N, Zhang Z, Guo S, Shen S, Li X. Yan N, et al. Among authors: guo s. Front Med (Lausanne). 2023 May 24;10:1130012. doi: 10.3389/fmed.2023.1130012. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37293311 Free PMC article.

9

Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data.

Yan N, Zhang H, Guo S, Zhang Z, Xu Y, Xu L, Li X. Yan N, et al. Among authors: guo s. Front Oncol. 2024 Jan 31;14:1353491. doi: 10.3389/fonc.2024.1353491. eCollection 2024. Front Oncol. 2024. PMID: 38357200 Free PMC article.

10

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study.

Shen S, Li X, Guo S, Xu L, Yan N. Shen S, et al. Among authors: guo s. Front Oncol. 2024 Jul 8;14:1391828. doi: 10.3389/fonc.2024.1391828. eCollection 2024. Front Oncol. 2024. PMID: 39040456 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,866 results

Search Page

Filters